Everolimus
Information
- Drug Name
- Everolimus
- Description
- Entry(CIViC)
- 28
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In-vitro study in 5 neuroblastoma cell lines (2 wi... | NRAS |
NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| The pretreatment tumor contained a somatic nonsens... | TSC2 |
TSC2 p.Gln1178Ter (p.Q1178*) ( ENST00000439673.6, ENST00000642365.2, ENST00000642797.1, ENST00000644043.1, ENST00000219476.9, ENST00000645186.2, ENST00000642561.1, ENST00000643088.1, ENST00000401874.7, ENST00000644329.1, ENST00000642206.2, ENST00000644335.1, ENST00000643946.1, ENST00000646388.1, ENST00000350773.9, ENST00000382538.10, ENST00000642936.1, ENST00000568454.6 ) TSC2 p.Gln1178Ter (p.Q1178*) ( ENST00000219476.9, ENST00000350773.9, ENST00000382538.10, ENST00000401874.7, ENST00000439673.6, ENST00000568454.6, ENST00000642206.2, ENST00000642365.2, ENST00000642561.1, ENST00000642797.1, ENST00000642936.1, ENST00000643088.1, ENST00000643946.1, ENST00000644043.1, ENST00000644329.1, ENST00000644335.1, ENST00000645186.2, ENST00000646388.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| The pretreatment tumor contained a somatic nonsens... | MTOR |
MTOR p.Phe2108Leu (p.F2108L) ( ENST00000361445.9, ENST00000703140.1 ) MTOR p.Phe2108Leu (p.F2108L) ( ENST00000361445.9, ENST00000703140.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase II trial on castration-resistant prosta... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| Tumors from 35 patients (12 with partial response ... | PTEN | PTEN MUTATION PTEN MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Archival tumor samples from 549 patients from the ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Archival tumor samples from 549 patients from the ... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| A phase 1 clinical trial identified a patient with... | MTOR | MTOR E2014K + E2419K MTOR E2014K + E2419K | Sensitivity | true | CIViC Evidence | detail |
| Tumors expressing TSC1 or TSC2 mutations show nota... | TSC1 | TSC1 LOSS-OF-FUNCTION TSC1 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| A panel of 31 breast cancer cell lines was tested ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a panel of 31 breast cancer cell lines, 11 had ... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | false | CIViC Evidence | detail |
| Case study of a 46-year old male patient with Peut... | STK11 |
STK11 p.Asp194Glu (p.D194E) ( ENST00000326873.12, ENST00000585465.3, ENST00000652231.1, ENST00000714322.1, ENST00000714323.1 ) STK11 p.Asp194Glu (p.D194E) ( ENST00000326873.12, ENST00000585465.3, ENST00000652231.1, ENST00000714322.1, ENST00000714323.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 5 NSCLC cell lines. Two LKB1 ... | STK11 |
STK11 LOSS ( ENST00000326873.12 ) STK11 LOSS ( ENST00000326873.12 ) |
Sensitivity | false | CIViC Evidence | detail |
| Case report of a 74-year old woman with EGFR- and ... | AKT2 |
AKT2 AMPLIFICATION ( ENST00000392038.7 ) AKT2 AMPLIFICATION ( ENST00000392038.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| Case report of a 74-year old woman with EGFR- and ... | RET | RET KIF5B-RET | Sensitivity | true | CIViC Evidence | detail |
| Case report of a 44-year-old patient with recurren... | PIK3CA |
PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R) ( ENST00000263967.4, ENST00000643187.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Case report of a 44-year-old patient with recurren... | PTEN | PTEN EXPRESSION PTEN EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| mTOR protein levels were found to underly a circad... | FBXW7 | FBXW7 LOSS-OF-FUNCTION FBXW7 LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| Ten patients with Neurofibromatosis 2 were enrolle... | NF2 | NF2 MUTATION NF2 MUTATION | N/A | true | CIViC Evidence | detail |
| A patient with metastatic bladder cancer that resp... | TSC1 |
TSC1 FRAMESHIFT TRUNCATION ( ENST00000298552.9 ) TSC1 FRAMESHIFT TRUNCATION ( ENST00000298552.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| A randomized, open-label phase 2 study, encompassi... | VHL | VHL LOSS-OF-FUNCTION VHL LOSS-OF-FUNCTION | Sensitivity | true | CIViC Evidence | detail |
| This study evaluated the effects of everolimus and... | BAP1 | BAP1 MUTATION BAP1 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a single-arm, open label phase 2 trial in PIK3C... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Sensitivity | false | CIViC Evidence | detail |
| PTEN loss is associated with reduced response to m... | PTEN |
PTEN DELETION ( ENST00000371953.8 ) PTEN DELETION ( ENST00000371953.8 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| A pre-clinical study in 10 solid cancer cell lines... | HRAS | HRAS MUTATION HRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| A case-study of a patient with urothelial carcinom... | MTOR | MTOR MUTATION MTOR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| 8 gastric cancer cell lines were treated with the ... | EIF4EBP1 | EIF4EBP1 PHOSPHORYLATION EIF4EBP1 PHOSPHORYLATION | Sensitivity | true | CIViC Evidence | detail |
| 54 patients with advanced gastric cancer were trea... | RPS6 | RPS6 PHOSPHORYLATION RPS6 PHOSPHORYLATION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01120249 | Active, not recruiting | Phase 3 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | April 1, 2011 | October 15, 2026 |
| NCT02057133 | Active, not recruiting | Phase 1 | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | March 10, 2014 | December 31, 2024 |
| NCT03324373 | Active, not recruiting | Phase 1 | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | March 20, 2019 | June 27, 2028 |
| NCT02962414 | Active, not recruiting | Phase 3 | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | June 8, 2017 | August 13, 2027 |
| NCT02811861 | Active, not recruiting | Phase 3 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | October 13, 2016 | July 31, 2024 |
| NCT03114527 | Active, not recruiting | Phase 2 | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | August 8, 2017 | December 2024 |
| NCT01805271 | Active, not recruiting | Phase 3 | Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy | March 2013 | June 2030 |
| NCT03065387 | Active, not recruiting | Phase 1 | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation | October 31, 2017 | October 1, 2025 |
| NCT04339062 | Active, not recruiting | Phase 1/Phase 2 | Cemiplimab in AlloSCT/SOT Recipients With CSCC | November 3, 2020 | January 1, 2025 |
| NCT02687958 | Active, not recruiting | Phase 2 | Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin | May 2015 | December 2023 |
| NCT02531932 | Active, not recruiting | Phase 2 | Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer | December 16, 2015 | March 2025 |
| NCT02397083 | Active, not recruiting | Phase 2 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer | September 23, 2015 | September 30, 2026 |
| NCT03697408 | Active, not recruiting | Phase 1/Phase 2 | Itacitinib + Everolimus in Hodgkin Lymphoma | February 11, 2019 | June 2027 |
| NCT01797523 | Active, not recruiting | Phase 2 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | October 7, 2013 | October 31, 2025 |
| NCT01734512 | Active, not recruiting | Phase 2 | PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children | December 13, 2012 | July 31, 2024 |
| NCT03049189 | Active, not recruiting | Phase 3 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | February 2, 2017 | December 2029 |
| NCT03577431 | Active, not recruiting | Phase 1/Phase 2 | Liver Transplantation With Tregs at MGH | March 29, 2019 | April 6, 2027 |
| NCT03284957 | Active, not recruiting | Phase 1/Phase 2 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | September 20, 2017 | December 29, 2027 |
| NCT03032406 | Active, not recruiting | Phase 2 | CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | January 23, 2017 | May 23, 2025 |
| NCT03950609 | Active, not recruiting | Phase 2 | Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors | July 30, 2019 | June 30, 2025 |
| NCT02321501 | Active, not recruiting | Phase 1 | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | June 22, 2016 | December 31, 2024 |
| NCT02228681 | Active, not recruiting | Phase 2 | Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer | May 21, 2015 | |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT02143726 | Active, not recruiting | Phase 2 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | October 1, 2014 | August 6, 2024 |
| NCT03386539 | Active, not recruiting | Phase 3 | Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score | January 29, 2018 | January 2024 |
| NCT04195750 | Active, not recruiting | Phase 3 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | February 27, 2020 | September 17, 2025 |
| NCT04188548 | Active, not recruiting | Phase 1 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | December 10, 2019 | December 2027 |
| NCT03740334 | Active, not recruiting | Phase 1 | Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL | January 30, 2019 | September 30, 2024 |
| NCT01674140 | Active, not recruiting | Phase 3 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | September 12, 2013 | January 2030 |
| NCT01087554 | Active, not recruiting | Phase 1 | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | March 2010 | August 18, 2026 |
| NCT02081755 | Active, not recruiting | Phase 4 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | March 2014 | June 2024 |
| NCT01582191 | Active, not recruiting | Phase 1 | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | May 14, 2012 | May 31, 2026 |
| NCT03216967 | Active, not recruiting | Phase 4 | Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia. | January 15, 2018 | November 2023 |
| NCT03008408 | Active, not recruiting | Phase 2 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | August 18, 2017 | August 31, 2028 |
| NCT03173560 | Active, not recruiting | Phase 2 | Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | August 17, 2017 | March 31, 2024 |
| NCT01217931 | Active, not recruiting | Phase 2 | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | January 19, 2011 | January 31, 2025 |
| NCT03493165 | Available | Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) | |||
| NCT00510068 | Completed | Phase 3 | Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors | July 2007 | March 2014 |
| NCT00514514 | Completed | Phase 3 | Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen | July 2007 | June 2015 |
| NCT00516412 | Completed | Phase 2 | Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | August 2007 | August 2012 |
| NCT00519324 | Completed | Phase 2 | Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer | August 2007 | |
| NCT00521001 | Completed | Phase 2 | Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery | January 2008 | December 2010 |
| NCT00553150 | Completed | Phase 1/Phase 2 | Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | March 2009 | November 15, 2019 |
| NCT00560963 | Completed | Phase 1/Phase 2 | Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine | October 2007 | January 2011 |
| NCT00570921 | Completed | Phase 2 | Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure | April 2008 | January 2015 |
| NCT00591734 | Completed | Phase 2 | RAD001 Plus Bevacizumab in Metastatic Melanoma | January 2008 | October 2011 |
| NCT00596557 | Completed | Phase 4 | Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up | February 2008 | July 2011 |
| NCT00597506 | Completed | Phase 2 | Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus | October 2007 | June 2010 |
| NCT00610948 | Completed | Phase 1 | Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment | March 2008 | January 2016 |
| NCT00618345 | Completed | Phase 2 | Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | March 2005 | August 2008 |
| NCT00634920 | Completed | Phase 4 | Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients | March 2008 | May 2013 |
| NCT00655655 | Completed | Phase 1 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | December 2004 | January 11, 2018 |
| NCT00658320 | Completed | Phase 3 | Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids | February 2008 | May 2012 |
| NCT00680758 | Completed | Phase 1 | Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | May 2008 | December 2010 |
| NCT00688623 | Completed | Phase 2 | RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe | June 24, 2009 | November 7, 2016 |
| NCT00702052 | Completed | Phase 2 | Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy | August 22, 2008 | April 20, 2012 |
| NCT00716573 | Completed | Phase 4 | Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure | September 16, 2008 | April 17, 2014 |
| NCT00756340 | Completed | Phase 1 | A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors | July 2008 | September 2015 |
| NCT00762632 | Completed | Phase 1/Phase 2 | Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia | December 2007 | |
| NCT00767819 | Completed | Phase 2 | Treatment of Patients With RAD001 With Progressive Sarcoma | March 31, 2008 | May 17, 2017 |
| NCT00770120 | Completed | Phase 2 | S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery | December 2008 | April 2014 |
| NCT00782626 | Completed | Phase 2 | Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas | June 2009 | August 2012 |
| NCT00789828 | Completed | Phase 3 | Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) | August 2009 | October 2014 |
| NCT00790036 | Completed | Phase 3 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | July 24, 2009 | June 15, 2016 |
| NCT00803816 | Completed | Phase 2 | Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A | November 2007 | December 2010 |
| NCT00805129 | Completed | Phase 2 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | December 5, 2008 | December 15, 2021 |
| NCT00805961 | Completed | Phase 2 | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM | January 2009 | May 2013 |
| NCT00814788 | Completed | Phase 2 | Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer | December 2008 | January 2016 |
| NCT00823459 | Completed | Phase 2 | Everolimus in Treating Patients With Recurrent Low-Grade Glioma | January 23, 2009 | November 13, 2017 |
| NCT00827359 | Completed | Phase 2 | Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma | March 2009 | June 2018 |
| NCT00863655 | Completed | Phase 3 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole | June 3, 2009 | December 4, 2014 |
| NCT00869999 | Completed | Phase 2 | Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | May 2009 | November 2011 |
| NCT00870337 | Completed | Phase 2 | Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer | March 2008 | |
| NCT00876395 | Completed | Phase 3 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer | September 10, 2009 | October 23, 2017 |
| NCT00879333 | Completed | Phase 3 | Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) | July 2009 | January 2014 |
| NCT00886691 | Completed | Phase 2 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | December 27, 2010 | March 23, 2015 |
| NCT00903175 | Completed | Phase 2 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma | October 2009 | May 2015 |
| NCT00912340 | Completed | Phase 2 | Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer | May 2009 | July 2017 |
| NCT00915603 | Completed | Phase 2 | Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | July 2009 | July 2014 |
| NCT00918333 | Completed | Phase 1/Phase 2 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | June 2009 | July 16, 2019 |
| NCT00930930 | Completed | Phase 2 | Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer | June 2009 | October 2014 |
| NCT00935792 | Completed | Phase 1/Phase 2 | Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | July 2009 | December 2015 |
| NCT00936702 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary | September 2009 | August 2013 |
| NCT00943956 | Completed | Phase 1 | Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer | January 2009 | December 2012 |
| NCT00949949 | Completed | Phase 1 | Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy | September 2009 | July 2014 |
| NCT00962507 | Completed | Phase 1 | Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | July 2009 | January 2013 |
| NCT00965094 | Completed | Phase 4 | Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients | December 2009 | June 2013 |
| NCT00967044 | Completed | Phase 1/Phase 2 | Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma | November 2009 | March 2014 |
| NCT00968591 | Completed | Phase 1 | Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency | November 2009 | |
| NCT00976573 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | April 2010 | September 2015 |
| NCT00976755 | Completed | Phase 2 | Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer | September 14, 2009 | August 8, 2019 |
| NCT00981162 | Completed | Phase 1 | Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | August 2009 | December 2012 |
| NCT00985192 | Completed | Phase 2 | Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer | September 2009 | May 2014 |
| NCT01005199 | Completed | Phase 2 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer | November 2009 | March 2016 |
| NCT01007942 | Completed | Phase 3 | Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer | October 2009 | June 2015 |
| NCT01014351 | Completed | Phase 2 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | February 2010 | August 2013 |
| NCT01017029 | Completed | Phase 4 | Everolimus in de Novo Heart Transplant Recipients | September 2009 | December 2013 |
| NCT01023815 | Completed | Phase 3 | Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. | April 2009 | July 2012 |
| NCT01024946 | Completed | Phase 2 | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | December 2009 | July 2012 |
| NCT01031446 | Completed | Phase 1/Phase 2 | Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer | October 2009 | August 2017 |
| NCT01034631 | Completed | Phase 1/Phase 2 | BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma | January 2010 | December 2016 |
| NCT01035229 | Completed | Phase 3 | Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. | April 2010 | October 2013 |
| NCT01046045 | Completed | Phase 4 | Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients | April 2008 | June 2013 |
| NCT01058655 | Completed | Phase 1/Phase 2 | RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer | February 2010 | April 2015 |
| NCT01059318 | Completed | Phase 2 | A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis | January 2010 | June 2012 |
| NCT01070316 | Completed | Phase 1/Phase 2 | Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) | January 2010 | April 2016 |
| NCT01075321 | Completed | Phase 1/Phase 2 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | January 10, 2011 | February 13, 2020 |
| NCT01077986 | Completed | Phase 1/Phase 2 | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer | August 2009 | August 2011 |
| NCT01088048 | Completed | Phase 1 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | March 25, 2010 | April 28, 2015 |
| NCT01107509 | Completed | N/A | Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers | October 1, 2010 | October 1, 2017 |
| NCT01108445 | Completed | Phase 2 | Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma | September 2010 | April 2015 |
| NCT01114529 | Completed | Phase 3 | Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients | August 9, 2010 | October 30, 2014 |
| NCT01242631 | Completed | Phase 2 | Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer | November 2010 | March 2014 |
| NCT00093639 | Completed | Phase 1/Phase 2 | Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate | August 2004 | August 2006 |
| NCT00096486 | Completed | Phase 1/Phase 2 | Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer | May 2004 | July 2010 |
| NCT00097968 | Completed | Phase 3 | Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy | August 2004 | |
| NCT00098553 | Completed | Phase 2 | Everolimus in Treating Patients With Stage IV Melanoma | April 2005 | February 2010 |
| NCT00107237 | Completed | Phase 1/Phase 2 | AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme | October 2003 | June 2006 |
| NCT00150046 | Completed | Phase 3 | Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients | December 2004 | |
| NCT00154310 | Completed | Phase 4 | Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients | June 2005 | September 2008 |
| NCT00170820 | Completed | Phase 4 | Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen | February 2005 | |
| NCT00170833 | Completed | Phase 3 | Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients | November 2003 | |
| NCT00170859 | Completed | Phase 4 | Everolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients | August 2004 | December 2006 |
| NCT00170885 | Completed | Phase 4 | Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients | May 2005 | July 2007 |
| NCT00187174 | Completed | Phase 1 | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors | October 2004 | October 2008 |
| NCT00223054 | Completed | Polymorphism of the Cytochrome P450-system in Renal Transplants | March 2005 | October 2006 | |
| NCT00251004 | Completed | Phase 3 | Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients | October 2005 | October 2009 |
| NCT00255788 | Completed | Phase 2 | Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer | May 10, 2005 | January 18, 2011 |
| NCT00267189 | Completed | Phase 3 | RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency | November 2005 | November 2007 |
| NCT00276575 | Completed | Phase 1 | Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors | March 2005 | September 2014 |
| NCT00286624 | Completed | Phase 1/Phase 2 | Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation | March 2003 | August 2006 |
| NCT00300274 | Completed | Phase 3 | Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection | January 2006 | July 2011 |
| NCT00331409 | Completed | Phase 2 | Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | January 2006 | January 2010 |
| NCT00352443 | Completed | Phase 1 | S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | September 2006 | September 2013 |
| NCT00377962 | Completed | Phase 4 | Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation | December 2005 | February 2010 |
| NCT00378014 | Completed | Phase 3 | Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy | August 2006 | January 2013 |
| NCT00387400 | Completed | Phase 1 | Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme | March 20, 2007 | January 6, 2012 |
| NCT00402532 | Completed | Phase 3 | Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation | March 2005 | December 2011 |
| NCT00411619 | Completed | Phase 1/Phase 2 | Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | January 2007 | January 2014 |
| NCT00412061 | Completed | Phase 3 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor | December 2006 | June 2013 |
| NCT00414440 | Completed | Phase 4 | Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease | December 2006 | October 2013 |
| NCT00423865 | Completed | Phase 1 | Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors | November 2006 | September 2011 |
| NCT00426556 | Completed | Phase 1 | Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer | July 2007 | March 2014 |
| NCT00434174 | Completed | Phase 1 | Safety of Everolimus and Pemetrexed in Lung Cancer Patients | December 2006 | December 2010 |
| NCT00436618 | Completed | Phase 2 | Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment | August 2005 | October 9, 2019 |
| NCT00443937 | Completed | Phase 4 | Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients | January 2004 | March 2006 |
| NCT00458237 | Completed | Phase 1/Phase 2 | Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | April 2007 | April 2010 |
| NCT00464399 | Completed | Phase 3 | Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients | September 2006 | |
| NCT00466466 | Completed | Phase 1 | Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | April 2007 | |
| NCT01136733 | Completed | Phase 1/Phase 2 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | August 5, 2010 | February 8, 2018 |
| NCT01139138 | Completed | Phase 1/Phase 2 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer | June 2010 | June 2017 |
| NCT01154335 | Completed | Phase 1 | Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer | July 2010 | May 2013 |
| NCT01154439 | Completed | Phase 1 | Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2010 | September 15, 2015 |
| NCT01157858 | Completed | Phase 2 | Everolimus and LongActing Octreotide Trial in Polycystic Livers | June 2010 | July 2012 |
| NCT01164176 | Completed | Phase 2 | Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer | March 2010 | October 2014 |
| NCT01164267 | Completed | Phase 2 | Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) | March 2010 | |
| NCT01169701 | Completed | Phase 4 | 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients | August 2010 | March 2014 |
| NCT01183247 | Completed | Phase 4 | An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens | July 2008 | June 2010 |
| NCT01184326 | Completed | Phase 1 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | January 2011 | March 2017 |
| NCT01197170 | Completed | Phase 1 | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | September 7, 2010 | January 13, 2021 |
| NCT01204476 | Completed | Phase 1 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | October 2010 | |
| NCT01217177 | Completed | Phase 1 | A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer | December 2011 | April 2014 |
| NCT01218555 | Completed | Phase 1 | Study of Everolimus (RAD001) in Combination With Lenalidomide | September 9, 2010 | November 5, 2020 |
| NCT01229943 | Completed | Phase 2 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | October 15, 2010 | January 3, 2018 |
| NCT01231399 | Completed | Phase 1/Phase 2 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | February 2012 | July 2016 |
| NCT01231659 | Completed | Phase 2 | Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | August 9, 2011 | April 30, 2017 |
| NCT01239472 | Completed | Phase 4 | Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant | January 2011 | June 2015 |
| NCT00085566 | Completed | Phase 1/Phase 2 | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer | March 2004 | February 2008 |
| NCT01266148 | Completed | Phase 4 | SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance | November 2009 | December 2012 |
| NCT01266837 | Completed | Phase 4 | Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) | March 2011 | October 31, 2017 |
| NCT01270321 | Completed | Phase 2 | Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer | November 2010 | February 2019 |
| NCT01281514 | Completed | Phase 1 | A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer | December 14, 2010 | January 8, 2018 |
| NCT01281865 | Completed | Phase 1/Phase 2 | Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma | January 2011 | October 2013 |
| NCT01298713 | Completed | Phase 2 | Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer | March 2008 | September 12, 2018 |
| NCT01305941 | Completed | Phase 2 | A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases | September 2011 | October 16, 2017 |
| NCT01334502 | Completed | Phase 1 | Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma | March 2012 | August 2017 |
| NCT01338090 | Completed | 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors | April 2010 | March 2012 | |
| NCT01354301 | Completed | Phase 4 | Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate | May 2011 | December 2014 |
| NCT01387880 | Completed | Phase 2 | Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer | January 2010 | March 2012 |
| NCT01404325 | Completed | Phase 3 | Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients | February 1, 2012 | January 5, 2017 |
| NCT01408004 | Completed | Phase 2 | Rotating Pazopanib and Everolimus to Avoid Resistance | November 2011 | April 2014 |
| NCT01410448 | Completed | Phase 3 | Everolimus in de Novo Kidney Transplant Recipients | November 2011 | December 2015 |
| NCT01427946 | Completed | Phase 1/Phase 2 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | July 2011 | October 2014 |
| NCT01430572 | Completed | Phase 1 | Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | October 7, 2011 | May 12, 2020 |
| NCT01434602 | Completed | Phase 1/Phase 2 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | October 2, 2012 | July 13, 2021 |
| NCT01442090 | Completed | Phase 2 | Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy | October 2011 | July 2015 |
| NCT01453504 | Completed | Phase 1/Phase 2 | Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma | August 2012 | March 2019 |
| NCT01462214 | Completed | Phase 1/Phase 2 | Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer | October 2011 | January 2017 |
| NCT01466231 | Completed | Phase 2 | Everolimus in Refractory Testicular Germ Cell Cancer | November 2011 | June 2015 |
| NCT01469572 | Completed | Phase 1 | Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases | December 2011 | October 2018 |
| NCT01469884 | Completed | Phase 4 | Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients | November 2011 | April 2015 |
| NCT01470209 | Completed | Phase 1 | A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies | January 2012 | May 2017 |
| NCT01488487 | Completed | Phase 2 | Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | December 2011 | March 2015 |
| NCT01509560 | Completed | Phase 2 | PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood | November 1, 2011 | April 30, 2016 |
| NCT01523977 | Completed | Phase 1 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | November 2011 | November 2018 |
| NCT01524783 | Completed | Phase 3 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) | March 30, 2012 | August 7, 2020 |
| NCT01529554 | Completed | Phase 1/Phase 2 | Controlled Level EVERolimus in Acute Coronary Syndromes | January 8, 2015 | November 29, 2021 |
| NCT01551212 | Completed | Phase 4 | Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients | May 24, 2012 | August 8, 2017 |
| NCT01563354 | Completed | Phase 2 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial | August 16, 2013 | February 10, 2020 |
| NCT01566279 | Completed | N/A | A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03) | August 2012 | November 2016 |
| NCT01567488 | Completed | Phase 2 | Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET | June 8, 2011 | June 7, 2017 |
| NCT01594268 | Completed | Phase 4 | A Prospective, Open Label Study of CERtican in KIdney Transplantation | March 2012 | October 2013 |
| NCT01596140 | Completed | Phase 1 | Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | December 18, 2012 | June 1, 2020 |
| NCT01624766 | Completed | Phase 1 | Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers | June 19, 2012 | February 24, 2021 |
| NCT01624948 | Completed | Phase 4 | Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients | September 2012 | November 2015 |
| NCT01625377 | Completed | Phase 3 | A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients | December 2012 | March 2015 |
| NCT01636908 | Completed | N/A | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | August 2011 | December 1, 2019 |
| NCT01637194 | Completed | Phase 1 | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | November 2008 | July 2011 |
| NCT01642186 | Completed | Phase 2 | Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) | July 12, 2012 | July 16, 2021 |
| NCT01653041 | Completed | Phase 4 | Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors | August 2012 | April 2015 |
| NCT01661283 | Completed | Phase 2 | SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | September 2012 | December 2017 |
| NCT01665768 | Completed | Phase 2 | Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma | September 2012 | August 2020 |
| NCT01668784 | Completed | Phase 3 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | October 9, 2012 | July 19, 2021 |
| NCT01678664 | Completed | Phase 2 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors | October 2012 | April 2019 |
| NCT01680861 | Completed | Phase 3 | Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium | November 2012 | December 2014 |
| NCT01698918 | Completed | Phase 2 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | March 7, 2013 | January 13, 2021 |
| NCT01700400 | Completed | Phase 1 | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | September 2012 | October 2014 |
| NCT01714765 | Completed | Phase 1 | Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer | April 2011 | October 2012 |
| NCT01715935 | Completed | Phase 2 | Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus | June 2012 | April 2016 |
| NCT01780948 | Completed | N/A | Pharmacokinetic of Everolimus and Atorvastatin Co-administration | September 2012 | January 2013 |
| NCT01783444 | Completed | Phase 2 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | February 26, 2013 | July 30, 2018 |
| NCT01783756 | Completed | Phase 1/Phase 2 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | June 26, 2013 | May 10, 2019 |
| NCT01789281 | Completed | Phase 4 | Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. | May 14, 2013 | August 28, 2020 |
| NCT01797120 | Completed | Phase 2 | Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | May 31, 2013 | September 12, 2017 |
| NCT01804374 | Completed | Phase 2 | Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma | June 2011 | December 2014 |
| NCT01827384 | Completed | Phase 2 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | January 7, 2014 | October 8, 2021 |
| NCT01843348 | Completed | Phase 3 | 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients | December 27, 2012 | March 23, 2016 |
| NCT01854606 | Completed | Phase 1 | Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma | December 5, 2013 | June 1, 2016 |
| NCT01929642 | Completed | Phase 2 | Rapalogues for Autism Phenotype in TSC: A Feasibility Study | July 2013 | August 2016 |
| NCT01931163 | Completed | Phase 2 | NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer | July 2013 | January 2019 |
| NCT01976390 | Completed | N/A | Comparing Everolimus and Sirolimus in Renal Transplant Recipients | October 1, 2013 | August 31, 2019 |
| NCT02017860 | Completed | Phase 2 | Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. | January 16, 2014 | April 25, 2019 |
| NCT02028364 | Completed | Phase 2 | Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women | January 12, 2014 | August 9, 2021 |
| NCT02049047 | Completed | Phase 2 | Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy | February 2011 | January 2019 |
| NCT02056587 | Completed | Phase 4 | Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment | November 2011 | October 2013 |
| NCT02069093 | Completed | Phase 2 | Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | May 2014 | March 2016 |
| NCT02077556 | Completed | Phase 4 | Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients | April 2014 | January 15, 2019 |
| NCT02077933 | Completed | Phase 1 | Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors | May 14, 2014 | April 12, 2019 |
| NCT02084446 | Completed | Phase 4 | Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant | December 2012 | July 2017 |
| NCT02096107 | Completed | Phase 4 | Novartis Everolimus Transition | February 2014 | May 2017 |
| NCT02106507 | Completed | Phase 1 | ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate | April 2014 | June 28, 2021 |
| NCT02115113 | Completed | Phase 3 | REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy | March 28, 2014 | September 30, 2016 |
| NCT02120469 | Completed | Phase 1 | Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer | October 1, 2014 | March 3, 2020 |
| NCT02123823 | Completed | Phase 1 | BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer | May 15, 2014 | December 14, 2021 |
| NCT02125084 | Completed | Phase 1 | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer | October 2014 | May 3, 2021 |
| NCT02134899 | Completed | Phase 3 | The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients | October 14, 2014 | November 11, 2017 |
| NCT02138929 | Completed | Phase 1 | LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | November 10, 2014 | June 8, 2020 |
| NCT02152943 | Completed | Phase 1 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | July 17, 2014 | December 14, 2020 |
| NCT02155920 | Completed | Phase 2 | Everolimus for Children With Recurrent or Progressive Ependymoma | February 2015 | July 14, 2023 |
| NCT02201212 | Completed | Phase 2 | Everolimus for Cancer With TSC1 or TSC2 Mutation | September 2014 | June 2019 |
| NCT02205515 | Completed | Phase 1/Phase 2 | An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis | March 2016 | October 2021 |
| NCT02240719 | Completed | Phase 1 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | October 2014 | April 9, 2018 |
| NCT02248571 | Completed | Phase 4 | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | August 2014 | September 30, 2017 |
| NCT02258451 | Completed | Phase 2 | Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer | June 4, 2015 | October 28, 2022 |
| NCT02264665 | Completed | OPALINE : A Study Of Morbidity And Mortality At 2 Years | May 12, 2015 | November 18, 2019 | |
| NCT02283658 | Completed | Phase 2 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | November 14, 2014 | June 21, 2018 |
| NCT02291913 | Completed | Phase 2 | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | December 18, 2014 | January 31, 2019 |
| NCT02328963 | Completed | Phase 4 | Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A | May 2, 2014 | October 10, 2018 |
| NCT02332902 | Completed | Phase 2 | Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T | February 2015 | March 2016 |
| NCT02333565 | Completed | Phase 2 | Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas | January 22, 2015 | May 24, 2023 |
| NCT02334488 | Completed | Phase 3 | Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function | December 11, 2014 | July 3, 2020 |
| NCT02338609 | Completed | Phase 4 | Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 | December 17, 2014 | December 18, 2023 |
| NCT02352844 | Completed | Phase 2 | Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations | October 7, 2015 | August 15, 2017 |
| NCT02376985 | Completed | Phase 3 | Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT | March 26, 2015 | October 16, 2018 |
| NCT02429869 | Completed | Phase 4 | Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant | February 24, 2016 | January 31, 2018 |
| NCT02449538 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors | February 2015 | August 2016 |
| NCT02451696 | Completed | Phase 2 | A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD | January 2014 | December 28, 2017 |
| NCT02454478 | Completed | Phase 1 | Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | July 1, 2015 | May 29, 2017 |
| NCT02456857 | Completed | Phase 2 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | January 12, 2016 | May 24, 2023 |
| NCT02511639 | Completed | Phase 3 | Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients | July 30, 2014 | July 31, 2020 |
| NCT02520063 | Completed | Phase 1/Phase 2 | Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer | February 1, 2016 | December 2022 |
| NCT02599324 | Completed | Phase 1/Phase 2 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | December 1, 2015 | August 20, 2021 |
| NCT02711826 | Completed | Phase 1/Phase 2 | Treg Therapy in Subclinical Inflammation in Kidney Transplantation | September 20, 2016 | August 4, 2023 |
| NCT02724020 | Completed | Phase 2 | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | June 30, 2016 | October 13, 2020 |
| NCT02732119 | Completed | Phase 1/Phase 2 | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. | June 14, 2016 | February 25, 2020 |
| NCT02742051 | Completed | Phase 2 | A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer | June 2016 | March 14, 2020 |
| NCT02809404 | Completed | Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) | June 2015 | January 2017 | |
| NCT02812940 | Completed | Phase 2 | Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT | April 2016 | December 2020 |
| NCT02842749 | Completed | Phase 4 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | March 14, 2016 | February 22, 2024 |
| NCT02864706 | Completed | Phase 4 | SCHEDULE Follow Up Visit 5-7 yr | January 18, 2016 | September 25, 2017 |
| NCT02871791 | Completed | Phase 1/Phase 2 | Palbociclib With Everolimus + Exemestane In BC | August 24, 2016 | September 2021 |
| NCT02890069 | Completed | Phase 1 | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | October 14, 2016 | February 22, 2022 |
| NCT02915783 | Completed | Phase 2 | A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | February 20, 2017 | November 2, 2021 |
| NCT02954198 | Completed | N/A | Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients | December 1, 2016 | December 27, 2018 |
| NCT02970630 | Completed | Phase 2 | Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study | January 2017 | February 22, 2018 |
| NCT02973204 | Completed | Circulating Tumor Cells and Tumor DNA in HCC and NET | November 2016 | January 8, 2020 | |
| NCT03070301 | Completed | Phase 2 | A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | February 27, 2017 | January 31, 2024 |
| NCT03163667 | Completed | Phase 2 | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | September 6, 2017 | June 1, 2020 |
| NCT03176238 | Completed | Phase 3 | Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | March 29, 2013 | January 29, 2019 |
| NCT03245151 | Completed | Phase 1/Phase 2 | Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | November 16, 2017 | September 30, 2022 |
| NCT03285802 | Completed | Phase 2/Phase 3 | Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation | September 7, 2017 | February 12, 2019 |
| NCT03312738 | Completed | Phase 2 | A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor | September 15, 2017 | April 25, 2022 |
| NCT03328104 | Completed | Phase 1 | Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma | July 24, 2018 | June 29, 2023 |
| NCT03355794 | Completed | Phase 1 | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | November 14, 2017 | July 31, 2022 |
| NCT03387020 | Completed | Phase 1 | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | January 13, 2018 | April 1, 2020 |
| NCT03415750 | Completed | Phase 4 | Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants | November 2016 | May 2020 |
| NCT03468478 | Completed | Phase 4 | Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation | June 18, 2017 | August 23, 2021 |
| NCT03525834 | Completed | Phase 4 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | November 9, 2018 | September 25, 2020 |
| NCT03659136 | Completed | Phase 2 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | November 28, 2018 | May 11, 2022 |
| NCT03834740 | Completed | Early Phase 1 | A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | December 21, 2018 | February 18, 2022 |
| NCT04066114 | Completed | Phase 1/Phase 2 | Treg Modulation With CD28 and IL-6 Receptor Antagonists | December 11, 2019 | September 14, 2023 |
| NCT00655252 | No longer available | Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy | |||
| NCT05108740 | No longer available | MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer | |||
| NCT06301386 | Not yet recruiting | Phase 2 | Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients | April 1, 2024 | December 1, 2026 |
| NCT06382948 | Not yet recruiting | Phase 3 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | June 2024 | April 2028 |
| NCT06126588 | Not yet recruiting | Phase 2 | Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial | March 1, 2024 | May 1, 2028 |
| NCT06280950 | Not yet recruiting | Phase 2 | Expanding Liver Transplant Immunosuppression Minimization Via Everolimus | June 30, 2024 | June 1, 2029 |
| NCT05124431 | Not yet recruiting | Phase 2 | Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma | December 2021 | December 2024 |
| NCT04199026 | Not yet recruiting | Early Phase 1 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | January 31, 2025 | December 31, 2025 |
| NCT05843253 | Not yet recruiting | Phase 2 | Study of Ribociclib and Everolimus in HGG and DIPG | May 30, 2024 | May 30, 2034 |
| NCT06428396 | Not yet recruiting | Phase 2 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | June 26, 2024 | May 24, 2028 |
| NCT02813135 | Recruiting | Phase 1/Phase 2 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | August 3, 2016 | August 2027 |
| NCT05594095 | Recruiting | Phase 2 | SNF Platform Study of HR+/ HER2-advanced Breast Cancer | December 30, 2022 | December 1, 2026 |
| NCT05188118 | Recruiting | Early Phase 1 | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | February 24, 2023 | December 2025 |
| NCT02407509 | Recruiting | Phase 1 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus | June 17, 2013 | May 2024 |
| NCT02432560 | Recruiting | Safety and Durability of Sirolimus for Treatment of LAM | March 2015 | July 31, 2025 | |
| NCT05949658 | Recruiting | Phase 1 | Rapalog Pharmacology (RAP PAC) Study | May 15, 2024 | December 2028 |
| NCT04355858 | Recruiting | Phase 2 | Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | May 1, 2020 | April 1, 2025 |
| NCT05012371 | Recruiting | Phase 2 | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | February 16, 2022 | October 25, 2025 |
| NCT04485559 | Recruiting | Phase 1 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | December 9, 2020 | December 31, 2027 |
| NCT04542733 | Recruiting | N/A | The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus in Treatment of BK Virus Infection in Kidney Transplantation Recipient | February 10, 2021 | September 2025 |
| NCT05773274 | Recruiting | Phase 2 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial | January 12, 2024 | April 30, 2026 |
| NCT04919226 | Recruiting | Phase 3 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | December 21, 2021 | September 2027 |
| NCT05432518 | Recruiting | Early Phase 1 | Pilot Trial for Treatment of Recurrent Glioblastoma | June 27, 2023 | December 1, 2027 |
| NCT04185831 | Recruiting | Phase 2 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial | October 20, 2020 | October 2024 |
| NCT04185883 | Recruiting | Phase 1 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | December 17, 2019 | December 31, 2027 |
| NCT05613166 | Recruiting | Phase 2 | Adjunctive Everolimus Treatment of Refractory Epilepsy | November 2022 | March 2023 |
| NCT05293964 | Recruiting | Phase 1 | Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer | May 18, 2022 | September 8, 2025 |
| NCT05252585 | Recruiting | Phase 4 | A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | May 1, 2023 | February 21, 2026 |
| NCT05983107 | Recruiting | Phase 2 | Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer | July 20, 2023 | July 15, 2027 |
| NCT05933395 | Recruiting | Phase 2 | Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor | October 10, 2023 | October 2031 |
| NCT05954442 | Recruiting | Phase 3 | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype | September 13, 2023 | August 2026 |
| NCT05918302 | Recruiting | Phase 3 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. | October 27, 2023 | July 2028 |
| NCT05725200 | Recruiting | Phase 2 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | September 27, 2022 | December 31, 2040 |
| NCT05306340 | Recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | August 3, 2022 | March 31, 2026 |
| NCT04849533 | Recruiting | Phase 4 | Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial) | April 9, 2021 | July 2024 |
| NCT03955172 | Recruiting | N/A | Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection | December 3, 2020 | December 3, 2027 |
| NCT06105632 | Recruiting | Phase 3 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | January 9, 2024 | December 14, 2028 |
| NCT04665739 | Recruiting | Phase 2 | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | February 3, 2023 | July 1, 2025 |
| NCT04802759 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | June 20, 2021 | October 31, 2026 |
| NCT05563220 | Recruiting | Phase 1/Phase 2 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer | January 24, 2023 | August 31, 2026 |
| NCT05476939 | Recruiting | Phase 3 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 | September 29, 2022 | September 2031 |
| NCT03139747 | Suspended | Phase 2 | UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone | April 3, 2017 | May 30, 2022 |
| NCT03493152 | Temporarily not available | Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019) | |||
| NCT01677390 | Terminated | Phase 1 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | August 2012 | December 2013 |
| NCT00934895 | Terminated | Phase 1/Phase 2 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca | July 15, 2009 | August 12, 2015 |
| NCT00515086 | Terminated | Phase 2 | Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | August 2007 | August 2009 |
| NCT03578432 | Terminated | Early Phase 1 | Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy | May 4, 2018 | November 15, 2019 |
| NCT02134288 | Terminated | Early Phase 1 | Belatacept for Renal Transplant Recipients With Delayed Graft Function | April 2014 | January 18, 2019 |
| NCT02137837 | Terminated | Phase 3 | S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | May 2014 | December 31, 2019 |
| NCT03654040 | Terminated | Phase 1/Phase 2 | Liver Transplantation With Tregs at UCSF | April 22, 2021 | March 6, 2023 |
| NCT02188719 | Terminated | Phase 1 | Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation | December 17, 2014 | June 18, 2019 |
| NCT00420537 | Terminated | Phase 4 | Shift to Everolimus (RAD) Kidney Sparing Study | September 2006 | March 2009 |
| NCT02236572 | Terminated | Phase 2 | Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | November 29, 2014 | March 1, 2021 |
| NCT03839940 | Terminated | Phase 3 | Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer | February 15, 2019 | December 17, 2020 |
| NCT02254239 | Terminated | Phase 1 | Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | February 4, 2016 | December 12, 2018 |
| NCT01125293 | Terminated | Phase 1/Phase 2 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | April 2010 | August 2014 |
| NCT01133678 | Terminated | Phase 2 | Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck | May 4, 2010 | January 2015 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00402662 | Terminated | Phase 2 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | February 2006 | June 2006 |
| NCT01149434 | Terminated | Phase 1/Phase 2 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | September 2010 | August 2012 |
| NCT02269670 | Terminated | Phase 2 | Phase II Study of Everolimus Beyond Progression | November 25, 2014 | January 25, 2021 |
| NCT02273752 | Terminated | Phase 2 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | November 2014 | December 2015 |
| NCT04063865 | Terminated | Phase 3 | Everolimus Monotherapy as Immunosuppression After Liver Transplant | May 9, 2019 | July 2, 2020 |
| NCT02315625 | Terminated | Phase 2 | Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | April 8, 2015 | May 22, 2019 |
| NCT01185366 | Terminated | Phase 2 | Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | August 2010 | September 9, 2019 |
| NCT01198158 | Terminated | Phase 3 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | September 15, 2010 | December 16, 2017 |
| NCT01215136 | Terminated | Phase 2 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | December 2010 | April 24, 2018 |
| NCT00390364 | Terminated | Phase 2 | Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy | October 2006 | October 2007 |
| NCT01115803 | Terminated | Phase 1 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | March 2010 | June 2011 |
| NCT02338570 | Terminated | Phase 4 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) | July 2015 | February 2018 |
| NCT00373815 | Terminated | Phase 1 | Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease | September 2006 | October 2009 |
| NCT04258423 | Terminated | Phase 3 | Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function | December 19, 2019 | June 27, 2020 |
| NCT01239342 | Terminated | Phase 2 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | January 27, 2011 | September 19, 2018 |
| NCT00857259 | Terminated | Phase 2 | The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration | February 2009 | |
| NCT00332839 | Terminated | Phase 4 | Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients. | November 2005 | March 2013 |
| NCT01276834 | Terminated | Phase 4 | Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation | September 2010 | July 2012 |
| NCT01313390 | Terminated | Phase 1/Phase 2 | Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer | June 2009 | April 2011 |
| NCT01313559 | Terminated | Phase 2 | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | June 2011 | November 29, 2012 |
| NCT00117702 | Terminated | Phase 2/Phase 3 | Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus | October 2005 | May 2008 |
| NCT02504892 | Terminated | Phase 2 | Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer | July 21, 2015 | April 17, 2018 |
| NCT01374451 | Terminated | Phase 2 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET | June 2011 | February 2015 |
| NCT01379521 | Terminated | Phase 2 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC | June 2011 | June 2015 |
| NCT02539459 | Terminated | Phase 2 | Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus | September 23, 2015 | August 20, 2018 |
| NCT01412515 | Terminated | Phase 2 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | June 2008 | May 2011 |
| NCT02560012 | Terminated | Phase 2 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | January 4, 2016 | July 27, 2017 |
| NCT00831480 | Terminated | Phase 2 | Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal | April 2011 | December 2014 |
| NCT01473732 | Terminated | N/A | Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity | March 2012 | August 2012 |
| NCT01499160 | Terminated | Phase 2 | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | May 2012 | December 2016 |
| NCT01508104 | Terminated | Phase 1 | Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors | January 2012 | December 2014 |
| NCT00811590 | Terminated | Phase 2 | Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome | November 2008 | March 2011 |
| NCT01561404 | Terminated | Phase 4 | Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise | September 2011 | December 2013 |
| NCT01582009 | Terminated | Phase 1/Phase 2 | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | March 2010 | December 2015 |
| NCT01609673 | Terminated | N/A | Study of Everolimus in de Novo Renal Transplant Recipients | March 2013 | May 2013 |
| NCT01627067 | Terminated | Phase 2 | Exemestane-RAD001-Metformin | September 2012 | February 1, 2019 |
| NCT01628913 | Terminated | Phase 2 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | October 2012 | September 2014 |
| NCT01636466 | Terminated | Phase 3 | The Everolimus-Transplant Exit Strategy Trial (E-TEST) | June 2013 | May 2014 |
| NCT00809185 | Terminated | Phase 2 | RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes | November 2005 | March 2009 |
| NCT01637090 | Terminated | Phase 2 | Everolimus in Treating Cutaneous T-cell Lymphoma | June 2012 | May 2015 |
| NCT01648465 | Terminated | Phase 2 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors | August 6, 2012 | August 6, 2019 |
| NCT02974686 | Terminated | Phase 4 | Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation | November 2016 | September 2019 |
| NCT03014297 | Terminated | Phase 1 | Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression | March 6, 2017 | November 16, 2018 |
| NCT00727207 | Terminated | Phase 2 | Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy | May 2008 | September 2014 |
| NCT00674414 | Terminated | Phase 2 | Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery | April 2008 | |
| NCT00671112 | Terminated | Phase 1 | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | June 2008 | |
| NCT01009957 | Terminated | Phase 2/Phase 3 | Everolimus on CKD Progression in ADPKD Patients | June 2008 | June 2015 |
| NCT01773460 | Terminated | Phase 3 | Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane | July 2013 | July 2014 |
| NCT01784861 | Terminated | Phase 1/Phase 2 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | May 3, 2013 | August 19, 2020 |
| NCT01784978 | Terminated | Phase 2 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer | February 12, 2013 | May 8, 2017 |
| NCT01793636 | Terminated | Phase 2 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer | February 2013 | November 2015 |
| NCT01009801 | Terminated | Phase 1/Phase 2 | Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | February 2010 | June 2015 |
| NCT00651482 | Terminated | Phase 2 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | August 2008 | March 2012 |
| NCT00972335 | Terminated | Phase 2 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | January 2010 | July 2014 |
| NCT00582738 | Terminated | Phase 2 | Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection | December 2007 | January 2010 |
| NCT01878786 | Terminated | Phase 2/Phase 3 | A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys | June 2013 | December 2017 |
| NCT01888042 | Terminated | Phase 2 | Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer | July 2011 | July 2014 |
| NCT02023905 | Terminated | Phase 2 | Everolimus With and Without Temozolomide in Adult Low Grade Glioma | March 19, 2014 | September 30, 2021 |
| NCT03352427 | Terminated | Phase 2 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations | December 6, 2017 | May 15, 2019 |
| NCT02031536 | Terminated | Phase 2 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | April 10, 2014 | July 19, 2017 |
| NCT00526591 | Terminated | Phase 2 | Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer | September 2007 | August 2011 |
| NCT00954512 | Terminated | Phase 1/Phase 2 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | September 25, 2009 | June 7, 2011 |
| NCT03413722 | Unknown status | Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus | February 1, 2018 | December 1, 2021 | |
| NCT02015728 | Unknown status | N/A | Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors | December 2013 | December 2017 |
| NCT02091973 | Unknown status | N/A | MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation | June 2010 | December 2015 |
| NCT01631058 | Unknown status | Phase 4 | Renal Transplantation in the Elderly - nEverOld Study | July 2012 | June 2019 |
| NCT02036554 | Unknown status | Phase 4 | Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients | March 2013 | December 2015 |
| NCT03239015 | Unknown status | Phase 2 | Efficacy and Safety of Precision Therapy in Refractory Tumor | January 1, 2017 | December 31, 2023 |
| NCT03629847 | Unknown status | Phase 1/Phase 2 | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue | December 2012 | December 2018 |
| NCT02313051 | Unknown status | Phase 2 | Everolimus trIal for Advanced prememopausaL Breast Cancer Patients | December 2014 | December 2017 |
| NCT01118065 | Unknown status | Phase 2 | Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer | May 2010 | |
| NCT02025712 | Unknown status | Phase 2 | Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer | ||
| NCT01998789 | Unknown status | Phase 2 | Everolimus Post Orthotopic Liver Transplant | October 2013 | February 2019 |
| NCT02404051 | Unknown status | Phase 3 | Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer | December 2015 | January 2019 |
| NCT01525719 | Unknown status | Phase 2 | Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma | January 2012 | June 2014 |
| NCT02836847 | Unknown status | Phase 2 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | July 2016 | December 2020 |
| NCT00903188 | Unknown status | Phase 4 | Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation | October 2008 | April 2015 |
| NCT01216839 | Unknown status | Phase 2 | Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas | March 2011 | December 2013 |
| NCT01216826 | Unknown status | Phase 2 | Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma | March 2011 | December 2014 |
| NCT02013089 | Unknown status | N/A | A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study | December 2013 | December 2017 |
| NCT01088893 | Unknown status | Phase 2 | Everolimus in Breast Cancer Patients After Pre-operative Chemotherapy | November 2009 | March 2013 |
| NCT00888758 | Unknown status | Phase 4 | Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction | May 2009 | May 2011 |
| NCT05429684 | Unknown status | Phase 3 | Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer | January 1, 2021 | February 28, 2024 |
| NCT01608412 | Unknown status | Phase 4 | A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus | February 2012 | July 2014 |
| NCT02985125 | Unknown status | Phase 1/Phase 2 | LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy | May 4, 2017 | December 2022 |
| NCT01663805 | Unknown status | Phase 4 | Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population | January 2012 | June 2015 |
| NCT00799188 | Unknown status | Phase 3 | CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial | October 2008 | |
| NCT01167530 | Unknown status | Phase 1 | Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer | March 2008 | July 2014 |
| NCT01079702 | Unknown status | Phase 1/Phase 2 | Everolimus and Capecitabine in Patients With Advanced Malignancy | April 2008 | January 2011 |
| NCT02233049 | Unknown status | Phase 2 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | October 2014 | October 2018 |
| NCT00695344 | Unknown status | Phase 4 | Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant | January 2006 | June 2010 |
| NCT03580239 | Unknown status | Phase 3 | Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | January 1, 2019 | December 1, 2023 |
| NCT00890253 | Unknown status | Phase 2 | Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation | January 2010 | January 2013 |
| NCT03095040 | Unknown status | Phase 3 | CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma | December 16, 2016 | December 2021 |
| NCT00505102 | Unknown status | Phase 4 | Safe Renal Function In Long Term Heart Transplanted Patients | January 2007 | July 2009 |
| NCT01730209 | Unknown status | Phase 2/Phase 3 | Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex | November 2012 | November 2016 |
| NCT01960829 | Unknown status | Phase 2 | Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study | September 2013 | |
| NCT01423708 | Unknown status | Phase 2 | Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study | February 2010 | January 2014 |
| NCT00544999 | Unknown status | Phase 1 | Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia | September 2007 | |
| NCT02577458 | Unknown status | Phase 1 | Study of the Combination of CM082 With Everolimus in Patients With mRCC | September 2015 | June 2018 |
| NCT02493465 | Unknown status | Phase 4 | Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study | July 2015 | July 2017 |
| NCT01446484 | Unknown status | Phase 1/Phase 2 | Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection | October 2011 | November 2014 |
| NCT02616848 | Unknown status | Phase 1 | Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | November 2015 | |
| NCT01455649 | Unknown status | Phase 4 | Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults | November 2011 | November 2013 |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT02216786 | Unknown status | Phase 2 | A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer | January 2014 | July 31, 2020 |
| NCT04867720 | Unknown status | Phase 4 | Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients | March 16, 2021 | February 22, 2023 |
| NCT02450175 | Unknown status | N/A | Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls | June 2014 | June 2016 |
| NCT03154281 | Unknown status | Phase 1 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | July 17, 2017 | June 2024 |
| NCT00426049 | Unknown status | Phase 3 | Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation | October 2006 | |
| NCT01263951 | Unknown status | Phase 2 | Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone | November 2010 | May 2022 |
| NCT01864070 | Withdrawn | Phase 1 | Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | May 2014 | |
| NCT01269684 | Withdrawn | Phase 4 | Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients | August 2008 | August 2008 |
| NCT00855114 | Withdrawn | Phase 2 | Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery | July 2008 | June 2009 |
| NCT01234974 | Withdrawn | Phase 2 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | December 2010 | December 2013 |
| NCT01997255 | Withdrawn | Phase 2 | Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) | April 2014 | April 2016 |
| NCT03632317 | Withdrawn | Phase 2 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas | October 2019 | October 2025 |
| NCT02909335 | Withdrawn | Phase 3 | De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study | November 2016 | November 2021 |
| NCT02062892 | Withdrawn | Phase 4 | Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients | December 2013 | June 2014 |
| NCT02569125 | Withdrawn | Phase 2 | Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome | January 2016 | February 2016 |
| NCT01332279 | Withdrawn | Phase 1 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | April 2011 | May 2011 |
| NCT01178151 | Withdrawn | Phase 2 | Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome | October 2010 | April 2015 |
| NCT02860494 | Withdrawn | Phase 2/Phase 3 | Topical Everolimus in Patients With Tuberous Sclerosis Complex | December 2020 | December 2024 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Afinitor
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2009
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2010
- Target (Drug list of Screening Committee of Anticancer Drugs)
- mTOR
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 腎細胞がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- SEGA
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- NET
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 乳がん腎血管筋脂肪腫